Recent Advances in Endosonography—Elastography: Literature Review

Akira Yamamiya, Atsushi Irisawa *, Koki Hoshi, Akane Yamabe, Naoya Izawa, Kazunori Nagashima, Takahito Minaguchi, Masamichi Yamaura, Yoshitsugu Yoshida, Ken Kashima, Yasuhiro Kunogi, Fumi Sakuma, Keiichi Tominaga, Makoto Iijima and Kenichi Goda

Abstract: Ultrasonographic elastography is a modality used to visualize the elastic properties of tissues. Technological advances in ultrasound equipment have supported the evaluation of elastography (EG) in endosonography (EUS). Currently, the usefulness of not only EUS-strain elastography (EUS-SE) but also EUS-shear wave elastography (EUS-SWE) has been reported. We reviewed the literature on the usefulness of EUS-EG for various diseases such as chronic pancreatitis, pancreatic solid lesion, autoimmune pancreatitis, lymph node, and gastrointestinal and subepithelial lesions. The importance of this new diagnostic parameter, “tissue elasticity” in clinical practice might be applied not only to the diagnosis of liver fibrosis but also to the elucidation of the pathogeneses of various gastrointestinal diseases, including pancreatic diseases, and to the evaluation of therapeutic effects. The most important feature of EUS-EG is that it is a non-invasive modality. This is an advantage not found in EUS-guided fine needle aspiration (EUS-FNA), which has made remarkable progress in the field of diagnostics in recent years. Further development of artificial intelligence (AI) is expected to improve the diagnostic performance of EUS-EG. Future research on EUS-EG is anticipated.

Keywords: autoimmune pancreatitis; chronic pancreatitis; endoultrasoundography; gastro-intestinal lesion; lymph node; pancreatic solid lesion; shear wave elastography; strain elastography; subepithelial lesion

1. Introduction

Ultrasonographic elastography, based on covering strain and shear waves, is a modality used to visualize the elastic properties of tissues [1]. Reports in recent years have underscored the usefulness of extracorporeal ultrasonography (US) for ultrasound image enhancement for organs such as mammary, thyroid, and prostate glands. The usefulness of tissue elasticity in the gastrointestinal field for non-invasive and simple liver fibrosis diagnosis is widely acknowledged [2–6]. Technological advances in ultrasound equipment have made it possible to evaluate elastography in endosonography (EUS) [7,8]. In 2003, EUS–strain elastography (EUS-SE) was introduced. It is reportedly useful for clinical practice, for differentiating tumors, and for diagnosing chronic pancreatitis (CP). Strain elastography (SE) was initially a qualitative examination based on color patterns, but quantitative tissue elasticity diagnosis (strain ratio (SR), histogram analysis (SH)) can be performed by image processing. Nevertheless, because tissue elasticity cannot be measured using absolute values, it can only be used as a subjective measurement [9]. Shear wave elastography (SWE), which has been available since 2019, can objectively measure tissue
elastography using absolute values, in EUS. Reports of the usefulness of EUS–shear wave elastography (EUS-SWE) are emerging [10]. This review presents a summary of recent advances in EUS elastography (EUS-EG) for various diseases: CP, autoimmune pancreatitis (AIP), pancreatic solid lesions (PSL), lymphadenopathy, and gastrointestinal subepithelial lesions (GI-SEL).

2. Evaluating Elastography (EG) in Endoscopic Ultrasonography

2.1. Outline of the Evaluation Methods Using Elastography

Different evaluation methods are used for elastography of different types. Different types of EG are SE including acoustic radiation force impulse (ARFI) and SWE [9,11]. As explained herein, SE measures “strain,” which is correlated negatively with tissue elastic properties, whereas SWE measures shear wave velocity, which is correlated positively with true elastic properties. Today, both US and EUS can be used for SE and SWE [12].

2.2. Strain Elastography

Color pattern diagnosis is the qualitative evaluation method used for SE (Figure 1). Generally speaking, color pattern diagnosis is used for major color tones of tumors (blue, hard; red, soft), and for heterogeneous or homogeneous color tones. Giovannini et al. first reported the elastic score: a color pattern diagnosis. The elastic score, color pattern, and heterogeneity of distribution of the elastography were classified into five types [13]. The quantitative evaluation methods are classified into SR and SH. The former, SR, is the ratio of the target lesion strain to the peripheral tissue strain [14]. The latter, SH, evaluates a grayscale histogram created by converting an elastography image into a gray scale of 256 tones, thereby yielding feature values [15]. The mean value, which is one of the feature values, is reportedly correlated with the degree of pathological pancreatic fibrosis. The SH results, used along with neural network analysis (NN), are particularly valuable for differential diagnosis of pancreatic cancer from pancreatic inflammatory masses [16].

2.3. Shear-Wave Elastography

For SWE, only the quantitative evaluation method is used. Its values are measured as the shear-wave velocity ($V_s$) and are displayed in meters per second (m/s). After Ohno et al. conducted a clinical study to validate the suitability and usefulness of EUS-SWE, they reported the success rate of pancreatic parenchymal measurement as higher than 96%.
The median accuracy of measurement was 74% [17]. For site measurement of pancreatic parenchyma hardness, the error might be caused by compression by the endoscope.

3. Endoultrasonography (EUS)-Elastography for Various Diseases
3.1. Chronic Pancreatitis/Autoimmune Pancreatitis

For CP/AIP evaluation, understanding an EUS-EG image of a normal pancreas is fundamentally important. A normal pancreas is often portrayed homogeneously in green on EUS-EG. Reportedly, the pancreas hardness increases with age [18,19].

3.1.1. Chronic Pancreatitis

In fact, CP has a higher degree of hardness than a normal pancreas (Figure 2). Generally speaking, CP appear as blue and heterogeneous on EUS-EG as the disease progresses, which correlates with the Rosemont classification [11,15,20]. Kim et al. have described a mean SR of 3.78 ± 1.35 for a normal pancreas and 8.21 ± 5.16 for CP. Using a cut-off value of 5.62, the sensitivity, specificity, and accuracy of SR for detecting CP were, respectively, 72%, 75%, and 75% [21]. Several published reports have described the usefulness of EUS-EG for CP (Table 1).

![Figure 2. Endosonography (EUS) elastography in chronic pancreatitis.](image_url)

Yamashita et al. assessed the utility of EUS-SWE for CP diagnosis [22]. Results of that study indicate that vs. has a significant and positive correlation with the Rosemont classification and several EUS features of CP. In fact, the EUS-SWE results were consistent with CP ($V_s$ 2.98 m/s) and were suggestive of CP ($V_s$ 2.95 m/s). Moreover, the results were significantly higher than those found for normal tissue ($V_s$ 1.52 m/s). Actually, EUS-SWE also showed high accuracy for diagnosing CP, with an area under the receiver operating characteristic (AUROC) curve of 0.97. The vs. cut-off of 2.19 m/s showed 100% sensitivity and 94% specificity when diagnosing CP.

However, the diagnosis of CP using the Rosemont classification is based solely on EUS findings. Moreover, its evaluation is hindered by interobserver reliability [23,24]. Earlier reports have explored the putative relation between pancreatic function tests and EUS findings. Yamashita et al., using the Japanese version of the Diagnostic Criteria for Chronic Pancreatitis (DCCP2009) for support, conducted a prospective study elucidating the relation between CP diagnosis and EUS-SWE [25-28].

The EUS-SWE results found for groups of patients with probable CP ($V_s$ 2.78 m/s) and definite CP ($V_s$ 3.08 m/s) were determined using DCCP2009. Consequently, the results were significantly higher than in the normal group ($V_s$ 1.36 m/s). This method showed high accuracy for the diagnosis of CP (AUROC = 0.92), moderate accuracy for the diagnosis of exocrine dysfunction (AUROC = 0.78), and low accuracy (AUROC = 0.63) for the diagnosis of endocrine dysfunction. The vs. cut-off values of 1.96, 1.96, and 2.34 m/s for diagnosing CP, exocrine dysfunction, and endocrine dysfunction had 83%, 90%, and 75% sensitivity, respectively, and had 100%, 65%, and 64% specificity, respectively. Therefore,
it was possible to demonstrate the usefulness of EUS for diagnosing pancreatic exocrine insufficiency objectively, as described in existing reports, even using EUS-SWE.

Table 1. Usefulness of endosonography–elastography (EUS-EG) in chronic pancreatitis.

| Year | Number | Evaluation Method | Indeterminate for CP: 73.2 |
|------|--------|-------------------|-----------------------------|
| Kuwahara [11] | 2017 | 96 | Histogram |
| | | | Suggestive of CP: 63.7 |
| | | | Consistent with CP: 56.1 |
| Kim [21] | 2017 | 67 | Strain ratio |
| | | | Cut-off value: 5.62 |
| Yamashita [22] | 2020 | 52 | Shear wave |
| | | | Cut-off value: 2.19 m/s |
| Yamashita [27] | 2021 | 40 | Shear wave |
| | | | Cut-off value: 1.96 m/s |

CP, chronic pancreatitis.

Based on those findings, EUS-EG has played an important role in CP diagnosis and pancreatic function evaluation. Moreover, the absolute values of measurements taken using EUS-SWE can enable follow-up of temporal changes of CP from an early stage [29].

3.1.2. Autoimmune Pancreatitis

Ohno et al. described EUS-SWE effectiveness for assessing autoimmune pancreatitis (AIP) [12]. They found the median vs. to be significantly higher in patients with AIP (2.57 m/s) than in normal controls (1.89 m/s). Furthermore, mean vs. was found to be significantly lower in the former group after steroid treatment. These results provide new insights into pancreatic hardness, where it is high during active inflammation in AIP and decreased upon steroid therapy. Moreover, Dietrich et al. reported that pancreatic hardness might remain high after steroid treatment in AIP with a high risk of relapse. That hardness was implicated as an indicator for relapse assessment [30]. Furthermore, after they evaluated the utility of elastography for diagnosing AIP, they reported characteristic elastography patterns at the site of AIP masses and in the surrounding pancreatic tissue. Taken together, these reports support the use of EUS-EG for evaluating inflammatory activity in pancreatic inflammatory diseases such as AIP, although the study of more cases is necessary.

3.2. Pancreatic Solid Lesion

In general, EUS-EG shows pancreatic ductal carcinoma as a heterogeneous blue color because it is harder than the surrounding pancreatic parenchyma (Figure 3). Pancreatic endocrine tumors (P-NET), portrayed as blue, are homogeneous and harder than the surrounding pancreatic parenchyma. Mass-forming pancreatitis, having lower hardness than the surrounding area and heterogeneity, is shown as green. However, as chronic pancreatitis-like changes become more intense, the lesions become heterogeneous with higher hardness (blue color) than the surrounding areas, which might make it difficult to distinguish such lesions from pancreatic cancer. Numerous reports have described studies demonstrating the usefulness of EUS-EG for PSL (Tables 2–4).

The pattern classification for PSL was first reported by Giovannini et al. in 2006 [13]. After they performed EUS-EG on 24 PSL lesions, they inferred the lesions as malignant if they were almost entirely blue, and otherwise regarded them as benign. The sensitivity and specificity for malignancy were, respectively, 100% and 67%. Subsequently, the signals were classified into five score levels according to the degrees of distortion and signal distribution. This classification was later simplified. The differential diagnostic capabilities for benign and malignant lesions were evaluated in a multicenter study. The sensitivity and specificity of B-mode alone for PSL diagnosis were 92% and 69%, respectively, whereas those of EUS-EG were 92% and 80%, respectively [31]. Since then, Janssen and Iglesias-Garcia et al. have reported on the classification based on signal heterogeneity. They reported the ability to differentiate benign and malignant pancreatic masses with high
accuracy of 100% sensitivity and 85% specificity [32,33]. After Itokawa et al. used the same method, they found sensitivity of 96% and a positive diagnosis rate of 92% [14]. In addition, pancreatic diseases were classified into four groups: 1. normal control, 2. CP, 3. P-NET, and 4. pancreatic cancer. Results obtained from comparison of their scores showed that all normal control patients corresponded to Score 1. Almost all patients with pancreatic cancer corresponded to Score 5 (98%). Sáftoiu et al. reported that, when the mean cutoff was set to >175 using NN, the differential diagnosis ability between pancreatic cancer and inflammatory pancreatic masses was 91–93% in sensitivity and 66–78% in specificity [16]. That finding demonstrates that EUS-EG is useful for benign and malignant diagnosis of PSL. A meta-analysis revealed the following: integrated sensitivity was 95%, integrated specificity was 67%, and the odds ratio was 42.3 (95% CI 26.9–66.46) [13,16,31,33–42]. A meta-analysis of quantitative and qualitative methods found the sensitivity and specificity for pancreatic malignancies as 98% and 63%, respectively, for qualitative evaluation, and as 95% and 61%, respectively, for quantitative evaluation, indicating that each method has high sensitivity [13,14,19,31–47].

Some reports have argued that CH-EUS and EUS-EG, used in combination, can improve diagnostic performance. Chantarojanasiri et al. explained the diagnostic applicability of contrast-enhanced EUS (CH-EUS) and EUS-EG for EUS diagnosis of PSL [45]. In fact, the positive diagnosis rates of pancreatic cancer were found to be 68% for CH-EUS, 65% for EUS-EG, and 76% for CH-EUS+EUS-EG. A meta-analysis of 17 reports of the literature indicated the pooled sensitivity and specificity for qualitative methods as 98% and 63%, respectively, for qualitative evaluation, and as 95% and 61%, respectively, for quantitative evaluation, indicating that each method has high sensitivity [13,14,19,31–47].

### Table 2. Usefulness of histogram in pancreatic solid lesion.

| Year | Number | Prevalence of PDAC (%) | Cut-Off Value |
|------|--------|------------------------|---------------|
| Saftoiu [37] | 2010 | 54 | 61 | 175 |
| Iglesias-Garcia [34] | 2010 | 62 | 79 | 0.05 (elastic value) |
| Saftoiu [38] | 2011 | 258 | 82 | 170 |
| Opacic [43] | 2015 | 105 | 50 | 86 |

PDAC, pancreatic ductal adenocarcinoma.
In addition, results of a multicenter study on EUS-EG for small PSLs [53] have indicated that, based on qualitative evaluation of EUS-EG images, 218 PSLs of 15 mm or less were divisible into two groups: those that were harder than the surrounding area (hard lesions) and those that were equal to or softer than the surrounding area (soft lesions). Based on data from those two groups, the sensitivity, specificity, positive predictive value, and negative predictive value for pancreatic ductal carcinoma in hard lesions were found to be 96% (95% CI, 0.87–1.00), 64% (95% CI, 0.56–0.71), 45% (95% CI, 0.40–0.50), and 98% (95% CI, 0.93–1.00), respectively. In that report, the author specifically examined the extremely high negative predictive value of 98%, inferring eventually that malignancy can be excluded with high probability when EUS-EG shows soft lesions.

Finally, the usefulness of EUS-SWE was reported specifically in 2020. Ohno et al. reported a retrospective study comparing the respective diagnostic performances of EUS-SWE and EUS-SE for 64 PSLs [54]. The vs. (m/s) values of PSLs were reported as 2.56 for mass-forming pancreatitis, 2.19 for pancreatic cancer, 1.58 for metastatic tumors, and 1.31 for pancreatic neuroendocrine neoplasms. Actually, vs. showed no significant difference based on the disease. The mean strain values were 74.5 for mass-forming pancreatitis, 47.3 for pancreatic neuroendocrine neoplasms, and 45.5 for pancreatic cancer. Based on a comparison between pancreatic cancer and mass-forming pancreatitis in terms of tissue elasticity, vs. was found to have no significant difference (p = 0.5687). However, the mean strain value in pancreatic cancer cases was significantly lower: 45.4 vs. 74.5: p = 0.0007. Unexpectedly, vs. determined from EUS-SWE was found to have no significance among PSLs of different types.

The method of evaluating EUS-EG including EUS-SWE and differentiation of PSL was reviewed as follows: the evaluation methods of EG and their diagnostic abilities (sensitivity and specificity) were 82% (95% CI, 0.77–0.86) and 70% (95% CI, 0.64–0.76) for color pattern diagnosis, 94% (95% CI, 0.90–0.97) and 87% (95% CI, 0.81–0.92) for SR, 92% (95% CI, 0.90–0.94) and 79% (95% CI, 0.75–0.82) for SH, and 90 (95% CI, 0.82–0.95) and 82% (95% CI, 0.57–0.72) for SWE [2,13,14,19,21,22,32,34,37–43,45,47,54–63]. Therefore, EG and evaluation methods of many types are expected to be available: each has its own high diagnostic ability for PSL. Histological diagnosis by EUS-fine needle aspiration (EUS-FNA) is often necessary for the diagnosis of PSL; EUS-EG is useful as an adjunct diagnosis or as a method of screening before histological diagnosis.

Table 3. Usefulness of color pattern in pancreatic solid lesion.

| Year     | Number | Prevalence of PDAC (%) |
|----------|--------|------------------------|
| Giovannini [16] | 2006 | 24                      | 58                       |
| Jassen [32]     | 2007 | 33                      | 73                       |
| Hirche [57]     | 2008 | 70                      | 66                       |
| Giovannini [31] | 2009 | 121                     | 60                       |
| Iglesias-Garcia [33] | 2009 | 130                     | 59                       |
| Itokawa [14]    | 2011 | 109                     | 66                       |
| Lee [58]        | 2013 | 35                      | 43                       |
| Hocke [41]      | 2012 | 58                      | 33                       |
| Chantarojanasiri [45] | 2017 | 136                     | 69                       |
| Ignee [53]      | 2018 | 218                     | 51                       |

PDAC, pancreatic ductal adenocarcinoma.

3.3. Lymphoadenopathy

In addition to helping discriminate benign diseases, differential diagnosis of the lymph node (LN) can provide information for the staging of malignant diseases. Therefore, early and correct differentiation of benign and malignant LN is crucially important for clinical
decision-making. For the differential diagnosis of lymph nodes, EUS-EG shows benign nodes to be as hard (green) as their homogeneous surroundings. It also shows malignant nodes to be harder (blue) than their homogeneous surroundings.

Table 4. Usefulness of the strain ratio in pancreatic solid lesion.

| Year  | Number | Prevalence of PDAC (%) | Cut-Off Value |
|-------|--------|------------------------|---------------|
| Dawwas [39] | 2012 | 111 | 71 | 6.04 |
| Figueriedo [40] | 2012 | 47 | 70 | 8 |
| Havre [42] | 2014 | 48 | 23 | 3.05 |
| Kongkam [35] | 2015 | 38 | 61 | 3.17 |
| Mayerle [44] | 2016 | 91 | 53 | 10 |
| Rusebtmovic [59] | 2017 | 149 | 36 | 7.59 |
| Okasha [47] | 2017 | 172 | 56 | 7.8 |
| Kim [21] | 2017 | 157 | 57 | 8.86 |

PDAC, pancreatic ductal adenocarcinoma.

Giovanninni et al. first reported the differentiation of benign and malignant enlarged LN based on pathological diagnosis by EUS-guided fine needle aspiration (EUS-FNA) in 2006 [13]. They described sensitivity of 100% and specificity of 50% by pattern classification using the elastic score. A multicenter study later indicated sensitivity of 91% and specificity of 83% for the same pattern classification, which was significantly superior to B-mode diagnosis [31]. By contrast, Saftoiu et al. used SH analysis to differentiate between benign and malignant LN. Based on those findings, they reported high diagnostic performance: 92% sensitivity, 94% specificity, and a 93% positive diagnosis rate [64]. From one meta-analysis, integrated sensitivity of 88% and integrated specificity of 85% were found from 368 cases described in seven reports [13,31,64–69]. Therefore, EUS-EG is a promising, non-invasive method for differential diagnosis of malignant LNs. It might be a valuable supplemental method to EUS-FNA.

3.4. Gastrointestinal (GI)-Subepithelial Lesions

For diagnosis of GI-SELs, distinguishing between gastrointestinal stromal tumor (GIST) and other gastrointestinal mesenchymal tumor such as leiomyoma and Schwannoma is crucially important. Pathological diagnosis is possible using EUS-FNA, but results of EUS-FNA for SEL of 20 mm or less are not always reliable [70–72]. Therefore, differentiation by imaging diagnosis is valuable for the management of GI-SELs.

Tsuji et al. used the elastic score to classify patterns of 25 gastric SEL [71]. Their findings indicate that six out of nine gastrointestinal stromal tumors (GIST) had a score of 4, and that three out of nine had a score of 5 compared with the pathological diagnosis and elastic score, indicating that GIST are depicted as “hard” tissues compared with other SEL. In contrast, Ignee et al. reported difficulty in differentiating GIST from benign leiomyoma by pattern diagnosis using an elastic score [72]. The eventual utility of EUS-EG in this field remains unclear. Nevertheless, additional studies are warranted because of its high importance.

4. Limitations of EUS Elastography

Major limitations of EUS-EG include intra-observer and inter-observer variation from endoscopists with varying experience. Skill and experience among these valuable professionals is crucially important to obtain reproducible results [73]. Secondly, the pancreatic cancer detection rate of EUS-EG depends on tumor size, tumor volume, localization, and histological type. Furthermore, for EUS, some problems persist with accuracy, such as the need to rely on the heartbeat to compress the ultrasound probe [74].
5. Future Prospects of EUS-EG

As described in this review, non-invasive EUS-EG imaging method produces a variety of information. Nevertheless, endosonographers cannot be blinded to B-mode images obtained using EUS. Therefore, the possibility exists of bias in the accuracy of EUS-EG [75,76]. In addition, most studies address only lesions confirmed as malignant or benign. They exclude indeterminate lesions, which might unfairly increase the sensitivity and specificity of this technique. Currently, EUS-FNA/FNB is used widely as a fundamentally important examination method for the definitive diagnosis of not only PSL but also of lymphadenopathy [77,78]. However, a certain number of false-negative and false-positive cases persist. Their improvement is required. EUS-EG directs the appropriate puncture site, which might increase the accuracy of EUS-FNA/FNB. It is noteworthy that EUS-EG is especially useful in facilities where rapid onsite evaluation is not possible. In addition, the possibility of needle tract seeding should always be considered with EUS-FNA/FNB [79,80]. From this point of view, EUS-EG is important because it can be performed non-invasively. It is also expected that EUS-SWE will be compatible with all processors. The application of artificial intelligence (AI) to AI diagnosis and EUS-EG might lead to further improvement in diagnostic performance. Future research on EUS-EG is anticipated.

6. Conclusions

The development of EUS imaging has followed the progress in technologies applied for ultrasound equipment. The importance of this new diagnostic parameter, “tissue elasticity” in clinical practice might be applied not only to the diagnosis of liver fibrosis but also to the elucidation of the pathogeneses of various gastrointestinal diseases, including pancreatic diseases, and to the evaluation of therapeutic effects. We earnestly hope that EUS-EG can be exploited further by virtue of software and endoscopic hardware to become an even stabler and simpler diagnostic method.

Author Contributions: A.Y. (Akira Yamamiya) and A.I. designed this manuscript, collected and analyzed the data, and drafted the manuscript; A.I. checked the manuscript and approved the final version; K.H., A.Y. (Akane Yamabe), N.I., K.N., T.M., M.Y., Y.Y., K.K., Y.K. and F.S. collected the literature and created the tables; K.T., M.I. and K.G. supervised this manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest. Author Atsushi Irisawa is an Editor of this special issue in the Journal of Clinical Medicine.

References

1. Shiina, T. JSUM ultrasound elastography practice guidelines: Basics and terminology. J. Med. Ultrason. 2013, 40, 309–323. [CrossRef] [PubMed]
2. Uchida, H.; Hirooka, Y.; Itoh, A.; Kawashima, H.; Haru, K.; Nonogak, K.; Kasugai, T.; Ohno, E.; Ohmiya, N.; Niwa, Y.; et al. Feasibility of tissue elastography using transcutaneous ultrasonography for the diagnosis of pancreatic diseases. Pancreas 2009, 38, 17–22. [CrossRef] [PubMed]
3. Shiina, T.; Nitta, N.; Ueno, E.; Bamber, J.C. Real time tissue elasticity imaging using the combined autocorrelation method. J. Med. Ultrason. 2002, 29, 119–128. [CrossRef] [PubMed]
4. Nakashima, K.; Shiina, T.; Sakurai, M.; Enokido, K.; Endo, T.; Tsunoda, H.; Takada, E.; Umemoto, T.; Ueno, E. JSUM ultrasound elastography practice guidelines: Breast. J. Med. Ultrason. 2013, 40, 359–391. [CrossRef] [PubMed]
5. Tsutsumi, M.; Miyagawa, T.; Matsumura, T.; Kawazoe, N.; Ishikawa, S.; Shimokama, T.; Shiina, T.; Miyanaga, N.; Akaza, H. The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: Clinicopathological analysis. Int. J. Clin. Oncol. 2007, 12, 250–255. [CrossRef] [PubMed]
6. Kudo, M.; Shiina, T.; Moriyasu, F.; Iijima, H.; Tateishi, R.; Yada, N.; Fujimoto, K.; Morikawa, H.; Hirooka, M.; Sumino, Y.; et al. JSUM ultrasound elastography practice guidelines: Liver. J. Med. Ultrason. 2013, 40, 325–357. [CrossRef]
7. Rösch, T.; Lightdale, C.J.; Boltet, J.F.; Boyce, G.A.; Sivak, M.V., Jr.; Yasuda, K.; Heyder, N.; Palazzo, L.; Dancygier, H.; Schusdziarra, V. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N. Engl. J. Med. 1992, 326, 1721–1726. [CrossRef]
8. Hirooka, Y.; Itoh, A.; Kawashima, H.; Ohno, E.; Itoh, Y.; Nakamura, Y.; Hiramatsu, T.; Sugimoto, H.; Sumi, H.; Hayashi, D.; et al. Contrast-enhanced endoscopic ultrasonography in digestive diseases. J. Gastroenterol. 2012, 47, 1063–1072. [CrossRef]

9. Hirooka, Y.; Kuwahara, T.; Irisawa, A.; Ito, K.; Uchida, H.; Sasahira, N.; Kawada, N.; Itoh, Y.; Shinya, T. JSUM ultrasound elastography practice guidelines: Pancreas. J. Med. Ultrason. 2001, 42, 151–174. [CrossRef]

10. Yamashita, Y.; Kitano, M. Benefits and limitations of each type of endoscopic ultrasonography elastography technology for diagnosis of pancreatic diseases. Dig. Endosc. 2021, 33, 554–556. [CrossRef]

11. Kuwahara, T.; Hirooka, Y.; Kawashima, H.; Ohno, E.; Ishikawa, T.; Kawai, M.; Suhara, H.; Takeyama, T.; Hashizume, K.; Koya, T.; et al. Quantitative diagnosis of chronic pancreatitis using EUS elastography. J. Gastroenterol. 2017, 52, 868–874. [CrossRef]

12. Ohno, E.; Hirooka, Y.; Kawashima, H.; Ishikawa, T.; Tanaka, H.; Sakai, D.; Ishizu, Y.; Kuzuya, T.; Nakamura, M.; Honda, T. Feasibility and usefulness of endoscopic ultrasonography-guided shear-wave measurement for assessment of autoimmune pancreatitis activity: A prospective exploratory study. J. Med. Ultrason. 2019, 46, 425–433. [CrossRef] [PubMed]

13. Giovannini, M.; Hookey, L.C.; Bories, E.; Pesenti, C.; Monges, G.; Delpero, J.R. Endoscopic ultrasound elastography: The first step towards virtual biopsy? Preliminary results in 49 patients. Endoscopy 2006, 38, 344–348. [CrossRef] [PubMed]

14. Itokawa, F.; Itoi, T.; Sofuni, A.; Kurihara, T.; Tsuchiya, T.; Ishii, K.; Tsuji, S.; Ikeuchi, N.; Umeda, J.; Tanaka, R.; et al. EUS elastography combined with the strain ratio of tissue elasticity for diagnosis of solid pancreatic masses. J. Gastroenterol. 2011, 46, 843–853. [CrossRef] [PubMed]

15. Itoh, Y.; Itoh, A.; Hirooka, Y.; Ohno, E.; Nakamura, Y.; Hiramatsu, T.; Sugimoto, H.; Sumi, H.; Hayashi, D.; Kuwahara, T.; et al. Quantitative analysis of diagnosing pancreatic fibrosis using EUS-elastography (comparison with surgical specimens). J. Gastroenterol. 2014, 49, 1183–1192. [CrossRef] [PubMed]

16. Saitou, A.; Vilman, P.; Gorunescu, F.; Gheonera, D.I.; Gorunescu, M.; Ciurea, T.; Popescu, G.L.; Iordache, A.; Hassan, H.; Iordache, H. Neural network analysis of dynamic sequences of EUS elastography for the differential diagnosis of chronic pancreatitis and pancreatic cancer. Gastrointest. Endosc. 2008, 68, 1086–1094. [CrossRef]

17. Ohno, E.; Hirooka, Y.; Kawashima, H.; Ishikawa, T.; Ito, T.; Suhara, H.; Takeyama, T.; Hashizume, K.; Koya, T.; et al. Interobserver reliability of endoscopic ultrasonography: Literature review. J. Clin. Med. 2020, 10, 1851. [CrossRef]

18. Janssen, J.; Papavassiliou, I. Effect of aging and diffuse chronic pancreatitis on pancreas elasticity evaluated using semiquantitative EUS elastography. Ultraschall Med. 2014, 35, 253–258. [CrossRef]

19. Chantarojenasiri, T.; Hirooka, Y.; Kawashima, H.; Ohno, E.; Sugimoto, H.; Hayashi, D.; Kuwahara, T.; Yamamura, T.; Funasaka, K.; Nakamura, M.; et al. Age-related changes in pancreatic elasticity: When should we be concerned about their effect on strain elastography? Ultraschall Med. 2016, 37, 90–96. [CrossRef] [PubMed]

20. Catalano, M.F.; Lahoti, S.; Geenen, J.E.; Hogan, W.J. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. Gastrointest. Endosc. 1998, 48, 11–17. [CrossRef]

21. Yamashita, Y.; Tanioka, K.; Kawaji, Y.; Tamura, N.; Ito, T.; Hatamaru, K.; Itokawa, T.; Yoshida, T.; Yada, I.; Maekita, T.; et al. Utility of elastography with endoscopic ultrasonography shear-wave measurement for diagnosing chronic pancreatitis. Gut Liver 2020, 14, 659–664. [CrossRef]

22. Yamamiya, A.; Irisawa, A.; Kunogi, Y.; Nagashima, K.; Minaguchi, T.; Izawa, N.; Yamabe, A.; Hoshi, K.; Tominaga, K.; et al. Interobserver reliability of endoscopic ultrasound elastography: Literature review. Diagnostics 2020, 10, 953. [CrossRef] [PubMed]

23. Yamamiya, A.; Irisawa, A.; Tominaga, K.; Tsuchida, K.; Sugaya, T.; Tsunemi, M.; Hoshi, K.; Jinmai, H.; Yamabe, A.; Izawa, N.; et al. Interobserver reliability of the endoscopic ultrasound criteria for the diagnosis of early chronic pancreatitis: Comparison between the 2009 and 2019 Japanese Diagnostic Criteria. Diagnostics 2021, 11, 431. [CrossRef]

24. Catalano, M.F.; Lahoti, S.; Geenen, J.E.; Hogan, W.J. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. Gastrointest. Endosc. 1997, 48, 11–17. [CrossRef]

25. Lee, L.S.; Tabak, Y.P.; Kadiyala, V.; Sun, X.; Suleiman, S.; Johannes, R.S.; Banks, P.A.; Conwell, D.L. Diagnosis of Chronic Pancreatitis Incorporating Endosonographic Features, Demographics, and Behavioral Risk. Pancreatography, and Secretin Test in the Diagnosis of Chronic Pancreatitis. J. Gastroenterol. Hepatol. 2021, 36, 391–396. [CrossRef]

26. Shimesegawa, T.; Kataoka, K.; Kamisawa, T.; Miyakawa, H.; Ohara, H.; Ito, T.; Naruse, S.; Sata, N.; Suda, K.; Hirotw, M.; et al. The revised Japanese clinical diagnostic criteria for chronic pancreatitis. J. Gastroenterol. Hepatol. 2010, 45, 584–591. [CrossRef] [PubMed]

27. Takasaki, Y.; Ishii, S.; Fujisawa, T.; Ushio, M.; Takahashi, S.; Yamagata, W.; Ito, K.; Suzuki, A.; Ochiai, K.; Tomishima, K.; et al. Endoscopic ultrasonography findings of early and suspected early chronic pancreatitis. Diagnostics 2020, 10, 1018. [CrossRef] [PubMed]

28. Dietrich, C.F.; Hirsche, T.O.; Ott, M.; Igree, A. Real-time tissue elastography in the diagnosis of autoimmune pancreatitis. Endoscopy 2009, 41, 718–720. [CrossRef]
31. Giovannini, M.; Thomas, B.; Erwan, B.; Christian, P.; Fabrice, C.; Benjamien, E.; Geneviève, M.; Paolo, A.; Pierre, D.; Robert, Y.; et al. Endoscopic ultrasound elastography for evaluation of lymph nodes and pancreatic masses: A multicenter study. World J. Gastroenterol. 2009, 15, 1587–1593. [CrossRef]
32. Jensen, J.; Schlör, E.; Greiner, L. EUS elastography of the pancreas: Feasibility and pattern description of the normal pancreas, chronic pancreatitis, and focal pancreatic lesions. Gastrointest. Endosc. 2007, 65, 971–978. [CrossRef]
33. Iglesias-Garcia, J.; Larino-Noia, J.; Dominguez-Munoz, J.E.; Forteza, J.; Dominguez-Munoz, J.E. EUS elastography for the characterization of solid pancreatic masses. Gastrointest. Endosc. 2009, 70, 1101–1108. [CrossRef] [PubMed]
34. Iglesias-Garcia, J.; Larino-Noia, J.; Dominguez-Muno, J.E.; Forteza, J.; Dominguez-Munoz, J.E. Quantitative endoscopic ultrasound elastography: An accurate method for the differentiation of solid pancreatic masses. Gastroenterology 2010, 139, 1172–1180. [CrossRef] [PubMed]
35. Kongkam, P.; Lakananurak, N.; Rerknimitr, R.; Chantarojanasiri, T.; Aye, K.; Ridtitid, W.; Kritisin, K.; Angsuwatcharakon, P.; Aniwans, P.; Pittayanon, R.; et al. Combination of EUS-FNA and elastography (strain ratio) to exclude malignant solid pancreatic lesions: A prospective single-blinded study. J. Gastroenterol. Hepatol. 2015, 30, 1683–1689. [CrossRef] [PubMed]
36. Zhang, B.; Zhu, F.; Li, P.; Yu, S.; Zhao, Y.; Li, M. Endoscopic ultrasound elastography in the diagnosis of pancreatic masses: A meta-analysis. Pancreatology 2018, 18, 833–840. [CrossRef]
37. Saftoiu, A.; Iordache, S.A.; Gheonea, D.I.; Popescu, C.; Malos, A.; Gorunescu, F.; Ciurea, T.; Iordache, A.; Popescu, G.L.; Manea, C.T.L. Combined contrast-enhanced power Doppler and real-time sonoelastography performed during EUS, used in the differential diagnosis of focal pancreatic tumors (with videos). Gastrointest. Endosc. 2010, 72, 739–747. [CrossRef] [PubMed]
38. Saftoiu, A.; Vilmann, P.; Gorunescu, F.; Janssen, J.; Hocke, M.; Larsen, M.; Iglesias-Garcia, J.; Arcidiacono, P.; Will, U.; Giovannini, M.; et al. European EUS Elastography Multicentric Study Group. Accuracy of endoscopic ultrasound elastography used for differential diagnosis of focal pancreatic masses: A multicenter study. Endoscopy 2011, 43, 596–603. [CrossRef] [PubMed]
39. Dawwas, M.F.; Taha, H.; Leeds, J.S.; Nayar, M.K.; Oppong, K.W. Diagnostic accuracy of quantitative EUS elastography for the differential diagnosis of solid pancreatic masses: A prospective, single-center study. Gastrointest. Endosc. 2012, 76, 953–961. [CrossRef]
40. Figueiredo, F.A.; Da Silva, P.M.; Monges, G.; Bories, E.; Pesenti, C.; Caillol, F.; Delpero, J.R.; Giovannini, M. Yield of contrast-enhanced power Doppler endoscopic ultrasonography and strain ratio obtained by EUS- elastography in the diagnosis of focal pancreatic solid lesions. Endosc. Ultrason. 2012, 1, 143–149. [CrossRef]
41. Hocke, M.; Ignee, A.; Dietrich, C.F. Advanced endosonographic diagnostic tools for discrimination of focal chronic pancreatitis and pancreatic carcinoma elastography, contrast enhanced high mechanical index (CEHMI) and low mechanical index (CELM) endosonography in direct comparison. Z. Gastroenterol. 2012, 50, 199–203. [CrossRef] [PubMed]
42. Havre, R.F.; Odgaard, S.; Gilja, O.H.; Nesje, L.B. Characterization of solid focal pancreatic lesions by real-time elastography. Scand. J. Gastroenterol. 2014, 49, 742–751. [CrossRef] [PubMed]
43. Opacic, D.; Rustemovic, N.; Kalauz, M.; Markos, P.; Ostojic, Z.; Majerovic, M.; Ledinsky, I.; Višnjić, A.; Krznarić, J.; Opacic, M. Endoscopic ultrasound elastography strain histograms in the evaluation of patients with pancreatic masses. World J. Gastroenterol. 2015, 21, 4014–4019. [CrossRef] [PubMed]
44. Mayerle, J.; Beyer, G.; Simon, P.; Dickson, E.J.; Carter, R.C.; Duthie, F.; Lerch, M.M.; McKay, C.J. Prospective cohort study comparing transient EUS-guided FNA with EUS-FNA for the diagnosis of solid pancreatic mass lesions. Pancreatology 2016, 16, 110–114. [CrossRef] [PubMed]
45. Chantarojanasiri, T.; Hirooka, Y.; Kawashima, H.; Ohno, E.; Kuwahara, T.; Yamamura, T.; Funasaka, K.; Nakamura, M.; Miyahara, R.; Ishigami, M.; et al. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone versus the combination. Endosc. Int. Open. 2017, 5, E1136–E1143. [CrossRef]
46. Iglesias-Garcia, J.; Lindkvist, B.; Larino-Noia, J.; Abdulkader-Nallib, I.; Dominguez-Munoz, J.E. Differential diagnosis of solid pancreatic masses: Contrast enhanced harmonic (CEH-EUS), quantitative-elastography (QE-EUS), or both? United Eur. Endosc. Int. Open. 2017, 5, E1136–E1143. [CrossRef]
47. Okasha, H.; Elkholy, S.; El-Sayed, R.; El-Nabawi, M.; El-Nabawi, W.; El-Dayem, W.A.; Radwan, M.I.; Farag, A.; et al. Real time endoscopic ultrasound elastography and strain ratio in the diagnosis of solid pancreatic lesions. World J. Gastroenterol. 2017, 23, 5962–5968. [CrossRef]
48. Mei, M.; Ni, J.; Liu, D.; Jin, P.; Sun, L. EUS elastography for diagnosis of solid pancreatic masses: A meta-analysis. Gastrointest. Endosc. 2013, 77, 578–589. [CrossRef]
49. Dawwas, M.F.; Taha, H.; Leeds, J.; Oppong, K.W. The utility of quantitative endoscopic ultrasound elastography for the diagnosis of solid pancreatic masses. Gastroenterology 2011, 140, S-767. [CrossRef]
50. Badaoui, A.; Borbath, I.; Aouattah, T.; Gillain, C.; De Ronde, T.; Deprez, P.H. Evaluation of pancreatic tumors with contrast enhanced-endooscopic ultrasonography and EUS-strain ratio elastography. Gastrointest. Endosc. 2010, 71, AB281. [CrossRef]
51. Iordache, S.; Costache, M.I.; Popescu, C.F.; Streba, C.T.; Cazacu, S.; Saftoiu, A. Clinical impact of EUS elastography followed by EUS-FNA for the diagnosis of focal pancreatic masses. J. Clin. Med. 2021, 10, 3739.
75. Dietrich, C.F.; Săftoiu, A.; Jenssen, C. Real time elastography endoscopic ultrasound (RTE-EUS), a comprehensive review. *Eur. J. Radiol.* 2014, 83, 405–414. [CrossRef]

76. Deprez, P.H. EUS elastography: Is it replacing or supplementing tissue acquisition? *Gastrointest. Endosc.* 2013, 77, 590–592. [CrossRef]

77. Chen, J.; Yang, R.; Lu, Y.; Xia, Y.; Zhou, H. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for solid pancreatic lesion: A systematic review. *J. Cancer Res. Clin. Oncol.* 2012, 138, 1433–1441. [CrossRef]

78. Benafea, O.; Mghamga, F.P.; Zhao, J.; Zhao, R.; Zhu, L. Endoscopic ultrasonography with fine-needle aspiration for histological diagnosis of solid pancreatic masses: A meta-analysis of diagnostic accuracy studies. *BMC Gastroenterol.* 2016, 16, 108. [CrossRef]

79. Wang, K.X.; Ben, Q.W.; Jin, Z.D.; Du, Y.Q.; Zou, D.W.; Liao, Z.; Li, Z.S. Assessment of morbidity and mortality associated with EUS-guided FNA: A systematic review. *Gastrointest. Endosc.* 2011, 73, 283–290. [CrossRef]

80. Katanuma, A.; Maguchi, H.; Hashigo, S.; Kaneko, M.; Kin, T.; Yane, K.; Kato, R.; Kato, S.; Harada, R.; Osanai, M.; et al. Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas. *Endoscopy 2012, 44*, E160–E161. [CrossRef] [PubMed]